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Pregnancy has a minimal impact on the acute transcriptional
signature to vaccination
John S. Tregoning 1,7✉, January Weiner 2,6, Deniz Cizmeci1, Danielle Hake3, Jeroen Maertzdorf2, Stefan H. E. Kaufmann 2,
Geert Leroux-Roels4, Cathy Maes4, Annelies Aerssens4, Anna Calvert3 and Christine E. Jones3,5,7✉
Vaccination in pregnancy is an effective tool to protect both the mother and infant; vaccines against influenza, pertussis and
tetanus are currently recommended. A number of vaccines with a specific indication for use in pregnancy are in development, with
the specific aim of providing passive humoral immunity to the newborn child against pathogens responsible for morbidity and
mortality in young infants. However, the current understanding about the immune response to vaccination in pregnancy is
incomplete. We analysed the effect of pregnancy on early transcriptional responses to vaccination. This type of systems vaccinology
approach identifies genes and pathways that are altered in response to vaccination and can be used to understand both the acute
inflammation in response to the vaccine and to predict immunogenicity. Pregnant women and mice were immunised with
Boostrix-IPV, a multivalent vaccine, which contains three pertussis antigens. Blood was collected from women before and after
vaccination and RNA extracted for analysis by microarray. While there were baseline differences between pregnant and non-
pregnant women, vaccination induced characteristic patterns of gene expression, with upregulation in interferon response and
innate immunity gene modules, independent of pregnancy. We saw similar patterns of responses in both women and mice,
supporting the use of mice for preclinical screening of novel maternal vaccines. Using a systems vaccinology approach in
pregnancy demonstrated that pregnancy does not affect the initial response to vaccination and that studies in non-pregnant
women can provide information about vaccine immunogenicity and potentially safety.
npj Vaccines            (2020) 5:29 ; https://doi.org/10.1038/s41541-020-0177-6
INTRODUCTION
Vaccination of pregnant women (maternal vaccination) can
protect both the mother and her offspring from infection1.
Pregnancy is associated with dynamic adaptions of the immune
system throughout gestation to allow immunological tolerance of
the developing foetus2. During pregnancy, changes in the number
and function of immune cells have been observed, with enhanced
innate immune responses, as well as reduced numbers of B cells
and dendritic cells in the peripheral blood2–4. How these
differences could impact the response to vaccination in pregnancy
is incompletely understood, though recent studies suggest similar
antibody responses to influenza and pertussis vaccination in
pregnancy5–7. Understanding how pregnancy impacts on
responses to vaccines is important as new vaccines progress
through the vaccine pipeline with a specific indication for use in
pregnancy. These vaccines include respiratory syncytial virus (RSV),
group B Streptococcus (GBS) and potentially a monovalent
pertussis vaccine8.
Deeper understanding about the effect of pregnancy on
immunity will help to develop and optimise these vaccines, but
performing extensive immunological studies in pregnant women
is complicated by concerns of risk to mother and foetus. One
approach is to use systems vaccinology, which links the
transcriptomic (and other ‘omic’) responses to vaccine immuno-
genicity, efficacy and safety. Systems vaccinology has already led
to the identification of innate immune signatures at the individual
gene and gene module levels as predictors of vaccine
immunogenicity9,10.
Systems vaccinology has a number of potential advantages that
could accelerate the testing of vaccines10. Considerably more data
can be generated from fewer volunteers. Depending on the time
point that samples are collected, studies can be shorter since the
innate response occurs earlier after vaccination. The sampling is
relatively non-invasive as large data sets can be determined from
a single time point. Critically, systems vaccinology is capable of
generating entirely novel avenues of research because the
outputs are independent of pre-conceptions: the data are
generated and analysed using a non-hypothesis-driven metho-
dology and any differences can then be used to form new
hypotheses, which can be tested using other approaches11.
Systems vaccinology has yet to be applied to immunisation in
pregnancy but has the potential to make a significant contribution
to this important area of vaccine research especially because of
the ability to generate large data sets from smaller numbers of
volunteers. The incorporation of animal models into systems
vaccinology enables us to address questions that would not
otherwise be answerable in clinical studies, particularly with
regards to investigating injection sites or developing new
formulations.
One important question is how pregnancy alters the early gene
transcriptional responses to vaccination. The current study was
nested within the Biovacsafe consortium, which had the broader
aim of identifying biomarkers of vaccine safety12. These tran-
scriptomic profiles, particularly in genes relating to immune
function, have been proposed as biomarkers of inflammation after
immunisation. In the current study, we investigated the effect of
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pregnancy on the early response vaccination with Boostrix-IPV,
which is used in the UK to boost responses to Bordetella pertussis
(whooping cough) antigens. It is a multivalent vaccine that also
contains diphtheria, tetanus and inactivated polio virus (IPV)
antigens. We used RNA microarrays to measure the transcriptomic
response in both pregnant mice and women.
RESULTS
Vaccination induces a similar response in pregnant and non-
pregnant mice
Mice are a widely used preclinical model for understanding the
immune response to vaccination. They can be used to examine
the early response to vaccination, particularly at the site of
immunisation. To model changes after immunisation, we inves-
tigated responses in the mouse muscle, the site of immunisation.
Ten mice (five pregnant and five non-pregnant controls) were
immunised intramuscularly with Boostrix-IPV (produced by
GlaxoSmithKline containing diphtheria toxoid, tetanus toxoid,
IPV and three Bordetella pertussis antigens) and ten mice (five
pregnant and five non-pregnant controls) received saline as an
injection control. Pregnant mice were time mated and were
between 9 and 13 days of pregnancy, which is approximately the
second trimester of murine pregnancy (normally 19–21 days long).
Muscle samples were collected 24 h after immunisation, and the
extracted RNA was analysed by murine microarray analysis.
Initial analysis was performed using principal component
analysis (PCA), where the dimensionality of a large data set is
reduced to just two variables (the principal components) to
facilitate the interpretation of complex data sets while minimising
data loss. PCA suggested differences between the overall
transcriptomic response between the pregnant and non-
pregnant mice after immunisation with Boostrix (Fig. 1a) and
significant differences between pregnant and non-pregnant
animals injected with phosphate-buffered saline (PBS). The
experimental design for murine array analysis compared two
factors: pregnancy status (pregnant/non-pregnant control) and
vaccination status (Boostrix-IPV/placebo [PBS]). To further inves-
tigate whether pregnancy altered the global transcriptomic
response to vaccination, we conducted discordance/concordance
analysis using the disco R package13. The idea is that a heuristic
score combines the effect size estimates (log2 fold changes) and
the p values between two comparisons, thus providing a measure
that corresponds to concordance (when two genes are regulated
in the same direction) or discordance (when the two genes are
regulated in opposing directions). This shows that the response to
a vaccine is largely similar between pregnant mice and non-
pregnant control mice, with strong levels of concordance and low
levels of discordance (Fig. 1b). The difference to PCA is that disco
analysis is at an individual gene level, so it provides a more
detailed level of analysis.
To drill down into the response, we investigated modules that
had significant enrichment after vaccination (Fig. 1c). Vaccination
induced significant enrichment in several modules corresponding
to the interferon response (LI.M75, LI.M127 and LI.M150) and
innate sensing (LI.M111.1, LI.M13 and LI.M68). These changes were
observed in both non-pregnant control and pregnant animals—
reflecting the global concordance in changes in the disco analysis.
Interestingly, there were significant differences between pregnant
and non-pregnant animals 24 h after PBS injection, and these were
in clusters relating to cell cycling and adhesion, reflecting the PCA
(Fig. 1c, column 3).
The main question was whether the responses to immunisation
were different in pregnant and non-pregnant mice. To this end,
we have used two approaches. First, we used the disco metric13,
which allows to compare two comparisons (Fig. 1b). Here we
compared the immunisation-related changes in pregnant mice
with the changes recorded in non-pregnant mice. While this
approach allows visualisation and subsequent gene set enrich-
ment analysis, it does not provide per-gene p values. Second, we
directly interrogated the interaction term of the linear model for
each gene separately, thus obtaining both per-gene p values and
a gene set enrichment (Fig. 1c). Neither of these approaches
showed a significant effect of pregnancy on how the mice reacted
to immunisation.
Overall, there were 902 genes (351 upregulated, 551 down-
regulated: q-value < 0.05) differentially expressed between
vaccinated and PBS-treated non-pregnant animals (Fig. 2a) and
1559 genes (685 upregulated, 874 downregulated: q-value < 0.05)
differentially expressed in pregnant animals following Boostrix-IPV
vaccination (Fig. 2b). Previous systems vaccinology studies
investigating the response to vaccination with yellow fever
vaccine11 or inactivated influenza vaccine14 have observed a
significant upregulation of a number of interferon-stimulated
genes (ISG). We selected six individual genes that were
differentially expressed after immunisation in a range of other
studies (ISG15, OAS2, IFI44, RSAD2, C-X-C chemokine motif ligand
10 (CXCL10) and C-C chemokine motif ligand 2 (CCL2)). We
observed significant increases in ISG15 (Fig. 2c), OAS2 (Fig. 2d),
IFI44 (Fig. 2e) RSAD2 (Fig. 2f) and CCL2 (Fig. 2g) after immunisation
in both pregnant and non-pregnant mice; however, there was no
significant difference between Boostrix-IPV vaccinated pregnant
and non-pregnant mice. No significant difference was seen in
CXCL10 (Fig. 2h) after vaccination in pregnant or non-pregnant
mice. This data suggests that vaccination induces a similar early
response in both pregnant mice as well as non-pregnant mice.
Vaccination induces a similar response in pregnant and non-
pregnant women
Having observed that immunisation with Boostrix-IPV induces a
similar response in pregnant mice to non-pregnant mice, we
investigated the response in pregnant women. Thirty women at
16–32 gestational weeks were recruited at St George’s Hospital
(London, UK) and immunised with Boostrix-IPV (Table 1). Blood
samples were collected into PAXgene tubes immediately prior to
vaccination and 24 h later (range from 19 h 19min to 26 h 40min).
This study was a nested study within a larger study exploring
signatures of vaccine safety (BioVacSafe12). As a control, RNA
transcriptomic data from age-matched non-pregnant women was
used. Non-pregnant volunteers had been immunised with
Boostrix (Ghent, Belgium), had blood drawn at the same time
points and their samples were analysed on the same microarray
platform.
We repeated the analytical approach used in mice, initially
taking a global overview of the gene expression changes after
immunisation. PCA revealed an overlap between all samples, both
before and after vaccination (Fig. 3a). As seen with the mouse
data, using PCA, there was some separation between pregnant
and non-pregnant women: curiously, the non-pregnant group
were heterogeneous, both before and after vaccination, for
reasons that are unclear. To investigate whether pregnancy
altered the global transcriptomic response to vaccination, we
conducted discordance/concordance analysis using the DISCO
module13. This analysis indicated that the reactions to vaccination
are largely similar between non-pregnant and pregnant indivi-
duals (Fig. 3b). To investigate whether there were overall patterns
in gene expression after immunisation, we used bulk gene set
enrichment analysis. Comparing gene expression before and
after vaccination, significant increases were seen in similar
modules to the mouse, including modules corresponding to
interferon response (LI.M75, LI.M127 and LI.M150) and innate
sensing (LI.M111.1, LI.M13 and LI.M68), in both pregnant and non-
pregnant vaccinated women (Fig. 3c). The interferon module
(DC.M1.2) was upregulated in both groups and slightly larger in
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Fig. 1 Gene expression in the muscle is comparable 24 h after immunisation between pregnant and non-pregnant mice. Pregnant mice
and non-pregnant mice were intramuscularly immunised with Boostrix or PBS. Muscle tissue was extracted at 24 h after immunisation and
RNA extracted for analysis by microarray. a Principal component analysis (PCA) of gene expression. b Concordance/discordance (disco) plots
between comparisons in mouse data. Red colour indicates strong concordance (genes regulated in the same direction); blue colour indicates
strong discordance (genes regulated in opposite directions). c Gene set enrichment analysis of signature in the mouse muscle 24 h after
immunisation. Bar sizes correspond to effect size in the enrichment and the intensity of the colour to the p value of enrichment. Red and blue
boxes indicate the fractions of genes that have, respectively, a significantly higher or lower expression in the test group compared to the non-
pregnant group. N= 5 per group.
J.S. Tregoning et al.
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Fig. 2 Individual mouse genes in response to vaccination in pregnancy. Differential gene expression analysis comparing non-pregnant mice
(a) or pregnant (b) animals for all genes. Expression of individual differentially expressed genes (c–h), points represent individual animals, thick
dotted line represents median and thin dotted line represents quartiles. N= 5 per group. ***p < 0.001, **p < 0.01, *p < 0.05 by ANOVA and
post-test.
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the pregnant group after vaccination than in the non-pregnant
women, which suggests that the interferon response was stronger
in the pregnant women.
The gene set enrichment values were reflected in the individual
genes that were members of these gene sets with significant fold
changes. Overall, there were 2944 (1464 upregulated; 1480
downregulated; Benjamini–Hochberg (BH)-adjusted p value <
0.05) genes in response to immunisation with significant
differential expression before and after vaccination in non-
pregnant women (Fig. 4a) and 46 genes (41 upregulated; 5
downregulated; BH-adjusted p value < 0.05) following immunisa-
tion in pregnant women (Fig. 4b). We focussed on the same
individual ISGs investigated in the mouse study. We observed
significant increases in ISG15 (Fig. 4c), OAS2 (Fig. 4d), IFI44
(Fig. 4e), CCL2 (Fig. 4g) and CXCL10 (Fig. 4h) after immunisation in
pregnancy, but no change in RSAD2 (Fig. 4f).
While we did not analyse the immune responses to the
vaccines, a recent study has looked at the transcript levels as
baseline predictors of immunogenicity15. When comparing the
expression of the suggested marker genes from the published
study in pregnancy, we observed the following: among the genes
that were associated with a higher response when upregulated,
the genes ARRB1, DPP3 and ACTB were significantly higher
expressed in non-pregnant compared to pregnant women; there
was no difference in expression for MVP, PLEKHB2 or ARPC4 genes
and gene expression for GRB2 and RAB24 was higher in pregnant
women. Interestingly, four of the six genes that had significantly
reduced expression in high responders had lower expression in
pregnancy (Supplementary Fig. 1). Overall, vaccination induced a
very similar transcriptomic response at 24 h following Boostrix-IPV
vaccination in pregnant women and non-pregnant women, as
seen in the murine study.
Of mice and women
Since the human and mouse samples were analysed using a
similar microarray platform, it was possible to compare responses
to determine how predictive preclinical mouse models might be
for human responses to vaccination. While a direct statistical
comparison would not be appropriate, we used the discordance/
concordance method, which was developed specifically for
comparison between data sets from different species13, combined
with gene set enrichment analysis. The responses observed in
mice were largely concordant with the responses in humans. This
similarity in responses was seen in both the non-pregnant (Fig. 5a)
and pregnant groups (Fig. 5b). The concordant genes were
enriched in the interferon response (LI.M75, LI.M127 and LI.M150)
and innate sensing (LI.M111.1, LI.M13 and LI.M68) modules
(Fig. 5c, columns 1 and 3). One interesting finding was that a
number of T cell activity-related modules were discordant
between non-pregnant mice and non-pregnant women (Fig. 5c,
column 2). This was driven by several T cell-related genes: indeed,
a few of these genes show discordant behaviour between mouse
and human samples (Fig. 5d): while the vaccination appeared to
lower the expression of genes such as CD3G and GPR171 in
humans, in mice the effect was opposite. This finding is not unlike
previous comparisons of transcriptomic responses between mice
and humans16,17.
DISCUSSION
The current study investigated the effect of pregnancy on the
transcriptomic response after vaccination using mouse models
and blood collected during clinical studies in humans. Vaccination
induced significant upregulation of a number of genes, many of
which were in modules associated with innate immunity. We saw
a minor impact of pregnancy on the response to vaccination at
the global, module and individual gene level. The predominant
signal 24 h after vaccination was of innate immune responses,
with multiple modules associated with viral sensing and type I
interferons. It is also of note that there were broad similarities
between the response in pregnant women and mice after
vaccination. These data suggest that the immediate immune
response to a pertussis-containing vaccine is not affected by
pregnancy.
In this study, we investigated the effect of pregnancy on gene
expression after vaccination. It was somewhat surprising that the
responses to immunisation were similar in pregnancy and in non-
pregnant state in both mice and humans. Historically, it was
viewed that pregnancy is a period of immune modulation in order
to avoid rejection of the foetus, which expresses antigens foreign
to the maternal immune system. But this view has been
challenged by a number of studies, and it is now clear that this
is a simplistic view, and there are complex immune interactions
between the foetus and the mother18. What we see here is a
robust upregulation of innate immune response genes, particu-
larly in the ISG family, both in pregnancy and in non-pregnant
mice and humans. It has been proposed that innate immunity
may be augmented to compensate for modulated cellular
acquired immunity19. Alternatively, it is possible that there is local
suppression in the female genital tract and decidua at the feto-
maternal border during pregnancy, which we did not investigate
as we focussed on the systemic responses in blood after
intramuscular immunisation.
The individual genes with observed fold changes are likely to be
markers of vaccine-induced inflammation. While the study design
did not allow us to investigate the link between the gene
response and efficacy or immunogenicity, in previous systems
vaccinology studies where a link between gene signatures and
vaccine-specific immune responses have been explored, changes
were observed in similar genes11,14,20–22. The similar patterns of
gene expression after vaccination to previous studies and the lack
of difference between pregnant and non-pregnant individuals
supports the observations that pregnancy does not alter the
immune response to vaccination5–7. We also determined the
baseline transcriptome prior to vaccination: previous studies
have investigated whether there is a link between baseline gene
signatures and immunogenicity. When the gene signature in the
current study was compared to a meta-analysis of influenza
vaccine studies15, we did not see a consistent difference between
pregnant and non-pregnant women in genes that were associated
with increased expression in high responders to the vaccine.
Table 1. Characteristics of the study populations.
Characteristic Pregnant (n= 30) Control (n= 100) p value
Age, mean (SD) 33.2 (4.7) 27.0 (6.2) ***
Ethnicity, n (% Caucasian) 24 (80%) 99 (99%) ***
Approximate gestational age at the time of immunisation (median ± range) 23 weeks (19–32) N/A
N/A not available.
***p < 0.001.
J.S. Tregoning et al.
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Interestingly, of the genes with reduced expression associated
with high responders measured in the current study, PTPN22,
PURA, CASP6 and PPIB all had lower levels of expression in
pregnancy. The mechanistic impact of these genes on immuno-
genicity remains to be established. In addition to looking at
efficacy, induced gene sets can be used as a measure of
inflammation23. The similar magnitude of response between the
non-pregnant and pregnant groups also indicates that there is a
similar level of inflammation in response to vaccination, which
suggests that there is no specific signal from this data to suggest
an impact on safety associated with vaccination in pregnancy.
Systems vaccinology has largely been harnessed for design of
signatures of vaccine immunogenicity. Here we were also
interested in the inflammatory transcriptomic profile in the
context of safety. Numerous studies have demonstrated the
safety of vaccination during pregnancy24,25. A recently published
study26 from the same consortium (Biovacsafe) using the same
analytical approaches observed that the chemokines CXCL10 and
CCL2 were associated with vaccine-induced inflammation. We
Fig. 3 Gene expression in blood is comparable 24 h after immunisation between pregnant and non-pregnant women. Pregnant or non-
pregnant women were immunised with Boostrix, blood samples were collected at baseline (d0) and 24 h after immunisation (d1) and RNA was
extracted for analysis by microarray. a Principal component analysis (PCA) of whole-gene analysis. b Concordance/discordance (disco) plots
between comparisons in human data. Red colour indicates strong concordance (genes regulated in the same direction); blue colour indicates
strong discordance (genes regulated in opposite directions). c Gene set enrichment analysis of signature in blood 24 h after immunisation. Bar
sizes correspond to effect size in the enrichment, and the intensity of the colour to the p value of enrichment. Red and blue boxes indicate the
fractions of genes that have, respectively, a significantly higher or lower expression in the group of pregnant women (n= 30) compared to the
non-pregnant group of women (n= 100).
J.S. Tregoning et al.
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Fig. 4 Immunisation induces ISG, regardless of pregnancy status. Differential gene expression analysis comparing non-pregnant (a) or
pregnant (b) women. Individual differentially expressed genes (c–h), thick dotted line represents median and thin dotted line represents
quartile. N= 30 in the pregnant group, N= 100 in the non-pregnant group. ***p < 0.001, **p < 0.01, *p < 0.05 by ANOVA and post-test.
J.S. Tregoning et al.
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Fig. 5 Responses to vaccination during pregnancy are similar in humans and mice. Discordance/concordance plots human vs mouse. Each
dot corresponds to a single pair of orthologues. Horizontal axes show the log2 fold change in the tested comparison in murine data. Vertical
axes show the log2 fold change in the tested comparison in human data. Colours correspond to the discordance/concordance (disco) score.
Red colour indicates high concordance between species and blue colour indicates high discordance between species, i.e. genes regulated in
opposite directions. a Non-pregnant individuals; b pregnant individuals; c comparison of interactions between pregnancy and vaccination in
murine and human data. d Fold change between unvaccinated and vaccinated samples in mouse (X-axis) and human (Y-axis) samples.
J.S. Tregoning et al.
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found elevated levels of both of these gene transcripts after
vaccination, but there was no significant difference between
pregnant and non-pregnant individuals in either mouse or
humans, suggesting that there was no elevated inflammation
that could lead to increased reactogenicity in pregnancy. Here we
saw strong concurrence between mouse and human responses to
vaccination during pregnancy. Note that we were comparing
mouse muscle, the site of injection, with human blood, which is a
surrogate measure. Yet, similar profiles were seen in the blood and
the muscle, suggesting that the blood profile informs us about
what is happening locally at the injection site. Similar patterns
favour the mouse model as a predictive tool for understanding
inflammatory responses to vaccines in different conditions. While
the acute response to vaccination in the mouse closely reflected
that seen after human vaccination, there were some differences
seen, particularly in modules related to T cells. This reflects the
difference in immune experience between humans and experi-
mental (specific pathogen free) mice. Whether through vaccina-
tion or infection, adult humans are not naive for most of the
vaccine components in Boostrix-IPV, which may explain why there
were more T cell signatures in the blood. The gene modules that
we observed to be differentially upregulated in response to
Boostrix were recently shown to be upregulated in response to
adjuvanted influenza vaccine23, suggesting that there might be a
general response to injected/inactivated vaccines; though it was
of note that in the same study responses yellow fever vaccine, a
live attenuated virus, had a different kinetic.
This study was nested within a larger consortium (BioVacSafe),
which was established to investigate transcriptomic profiles of
vaccine safety. The Vaccination In Pregnancy (VIP) study was added
on after the main body of the study was performed. It is of note
that the two clinical studies were performed at different times, in
different locations. There was also a slight difference in the vaccine
used: the pregnant, UK cohort received Boostrix-IPV and the non-
pregnant Belgian cohort received Boostrix (no-IPV). The difference
in vaccine composure does not appear to have made a difference
in overall responses at 24 h. The mice used in the study were in
their middle trimester of pregnancy, similar as the women;
however, there will be differences as murine pregnancies are so
much quicker, which may affect interpretation of the data.
It was striking that the innate response to vaccination was not
affected by pregnancy. This is important because strategies to
boost immune responses to vaccines, for example through
adjuvants, may therefore be equally effective and safe in the
context of vaccination during pregnancy. The data suggests that,
at least in the context of early responses and vaccine safety,
studies in healthy non-pregnant women provide useful and
correct information about what can occur in pregnant women.
Given the pipeline of new vaccines targeted for use in pregnancy,
including RSV, GBS and monovalent pertussis8, tools that provide
greater understanding about the immune response to vaccines in
pregnancy are critical. Since acute gene responses are similar,
immunological insight derived from systems vaccinology studies
in non-pregnant individuals is applicable to pregnant individuals
thus accelerating the vaccine pipeline.
METHODS
The vaccine: Boostrix-IPV
Boostrix-IPV vaccine was used in mice and pregnant women. This vaccine
contains pertussis toxin (8 μg), filamentous haemagglutinin (8 μg) and
pertactin (2.5 μg) as well as diphtheria toxoid (not less than 2 international
units), tetanus toxoids (not less than 20 international units) and IPV types
1–3 (type 1 40 D-antigen unit, type 2 8 D-antigen unit, type 3 32 D-antigen
unit). Non-pregnant women received Boostrix, which contains the same
components as Boostrix-IPV at the same quantities but without IPV.
Ethics statement
The animal studies were approved by the Ethical Review Board of Imperial
College London, where the experiments were carried out and work was
performed in strict compliance with project and personal animal
experimentation licences granted by the UK government in accordance
with the Animals in Scientific Procedures Act (1986). There was a detailed
protocol in place, as required by the humane endpoints described in the
animal licence, for early euthanasia in the event of onset of illness or
significant deterioration in condition. At the end of the experiment, all
animals were culled by cervical dislocation and death confirmed before
necropsy. Food and water were supplied ad libitum.
The human study involving pregnant women (VIP gene signature: VIP
signature study) was approved by the London-Dulwich Research Ethics
Committee (17/LO/0698) and the NHS Health Research Authority.
ClinicalTrials.gov: NCT03284515.
Non-pregnant women were recruited in the context of another
Biovacsafe study (ClinicalTrials.gov: NCT02555540) that was approved by
the Ethics Committee of the Ghent University Hospital (2015/0693).
In both human studies, written informed consent was obtained from all
human participants.
Animals, immunisation and sampling
BALB/c mice of 6–8 weeks of age were purchased from Charles River
(Southampton, UK). Three female mice were housed with a single male,
which was then boxed out after 3 days. Females were checked for vaginal
plugs as an indicator of pregnancy and immunised 13 days after the male
was introduced: animals were therefore between 9 (E9) and 13 (E13) days of
pregnancy. Ten age-matched non-pregnant female mice were used as
controls. Pregnancy was confirmed post-mortem. Animals received a single
50 μl injection of Boostrix-IPV (equivalent to 1/10th of a human dose27) or
PBS in their right hind leg quadricep muscle and were culled 24 h after the
immunisation. There were five female mice in each group (pregnant/non-
pregnant receiving either Boostrix-IPV or PBS). When each animal was culled,
the injected muscle site was harvested and flash frozen in liquid nitrogen.
Total RNA preparation from tissue samples
Small pieces of mouse muscle tissue (3 mm× 3mm× 3mm) were
harvested and flash frozen in liquid nitrogen26. Total RNA isolation
(including microRNA (miRNA) species) was performed using the miRNeasy
Mini Kit (Qiagen, UK), as described in the standard protocol for purification
of miRNA and total RNA from tissues and cells. RNA was stored at −80 °C
until required for microarray hybridisation.
Whole-genome microarray analysis
Gene expression data were generated from high-quality RNA samples on an
Agilent microarray platform (Agilent Technologies). RNA was labelled with a
Low Input Quick Amp Labelling Kit (Agilent Technologies) according to the
manufacturer’s instructions. Quantity and labelling efficiency were verified
before hybridisation to whole-genome 8 × 60 k mouse expression arrays
(Agilent design ID 028005) and scanned at 5 μm using an Agilent scanner.
Image analysis and data extraction were performed with the Agilent’s Feature
Extraction software (version 11.5) to generate the raw expression data.
Humans
Pregnant women: VIP gene signature study. Pregnant women receiving
antenatal care at St George’s University Hospitals NHS Foundation Trust who
were between 16 and 32 weeks of pregnancy were eligible to participate.
Exclusion criteria included having received a pertussis containing vaccine
within the last 12 months and contraindications to vaccination according to
the ‘Green Book’ Immunisation against Infectious Disease.
After informed consent had been obtained, the first study visit was
arranged to take place between 16 and 32 weeks of pregnancy. At this visit,
all participants had a blood sample collected into a PAXgene tube followed
by administration of 1 dose (0.5ml) Boostrix-IPV into the deltoid muscle of
their non-dominant arm. A second blood sample was collected into a
PAXgene tube 24 h after vaccine administration and information was
collected about any adverse events that they had experienced.
Non-pregnant women. Non-pregnant women were recruited as part of a
larger cohort of healthy young adults who were given a single dose of
Boostrix (see above) in the deltoid muscle of the non-dominant arm. This
study aimed at finding predictive and early markers of vaccine safety. For
J.S. Tregoning et al.
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this survey, RNA isolated from the pre-vaccination and 24 h post-
vaccination blood samples, both collected in PAXgene® blood RNA tubes
(BD Biosciences), was used.
Transcriptome analysis/statistics
Data analysis was performed in R version 3.6.0 (2019-04-26). Microarray
data were pre-processed, normalised and analysed for differential
expression using R package limma v3.41.1528. The raw data were first
background corrected using the normexp method. Background corrected
signals were quantile normalised between arrays. Linear models were
fitted using the limma lmFit function. Differential expression was evaluated
using the moderated t-statistics, and all p values were corrected using the
BH approach to obtain q-values29. PCA was carried out using R prcomp
function. Genes that are orthologues in mice and humans were assigned
using NCBI HomoloGene30. Gene set enrichment analysis was performed
with R package tmod (version 0.34) using CERNO statistical test31,32. We
calculated p values corrected for multiple testing using the BH procedure
and the effect size area under curve of the gene set enrichment for blood
transcriptional modules (BTMs) defined by ref. 21. Highly concordantly as
well as highly discordantly regulated genes between tissues were
identified using the method described by Domaszewska et al.13. Magni-
tude of gene expression change (effect size), significance (adj. p value) and
direction of gene expression change were used to determine the
discordance/concordance score (using the R package disco). All scripts
and procedures are available online at https://cran.r-project.org/web/
packages/disco/index.html. Data on individual genes was plotted using
GraphPad Prism 8.0 (GraphPad Software) and analysed for significance by
Student’s t test or analysis of variance.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
The transcriptome data are available at GEO (https://www.ncbi.nlm.nih.gov/geo/) as a
SuperSeries (GSE144542) with two SubSeries (GSE144218—mouse data and
GSE144540—human data). The raw data for other figures are extracted from the
transcriptome data and available on request.
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